Dr. Mark A. Taylor
Claim this profileLewis Cancer and Research Pavilion at Saint Joseph's/Candler
Expert in Cancer
Expert in Lung Cancer
21 reported clinical trials
69 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Mark A. Taylor is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
More about Mark A. Taylor
Clinical Trial Related7 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Mark A. Taylor has experience with
- Pembrolizumab
- Carboplatin
- Nivolumab
- Abemaciclib
- Crizotinib
- Larotrectinib
Breakdown of trials Mark A. Taylor has run
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark A. Taylor specialize in?
Mark A. Taylor focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Mark A. Taylor currently recruiting for clinical trials?
Yes, Mark A. Taylor is currently recruiting for 9 clinical trials in Savannah Georgia. If you're interested in participating, you should apply.
Are there any treatments that Mark A. Taylor has studied deeply?
Yes, Mark A. Taylor has studied treatments such as Pembrolizumab, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Mark A. Taylor?
Apply for one of the trials that Mark A. Taylor is conducting.
What is the office address of Mark A. Taylor?
The office of Mark A. Taylor is located at: Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia 31405 United States. This is the address for their practice at the Lewis Cancer and Research Pavilion at Saint Joseph's/Candler.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.